CHICAGO, May 29, 2018 (GLOBE NEWSWIRE) -- BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it is now a resident company at Johnson & Johnson Innovation, JLABS (JLABS @ TMC) at the renowned Texas Medical Center.
Operating in Houston will play a critical role as BIOLIFE4D continues the development of its innovative technology and core mission of being able to 3D bioprint a viable human heart for transplant.
“This is a significant step forward for BIOLIFE4D in our quest to commercialize our 3D bioprinting technology and produce alternative viable treatment options for heart disease, such as patches, valves, and eventually, a human heart for transplant,” said Steven Morris, CEO, BIOLIFE4D. “Combined with our presence in Chicago and the agreements we signed with Northwestern University earlier this year, we have successfully penetrated two of the leading medical hubs in the world, and further positioned ourselves for success.”
Our presence in Houston furthers BIOLIFE4D’s deep relationship with the medical and scientific community within the state of Texas. A significant portion of the Company’s leadership, such as Chief Medical Officer Dr. Jeffrey Morgan and Chief Science Officer Dr. Ravi Birla, have noteworthy connections within the region, including the Texas Medical Center and Texas Heart Institute. Many of the other top heart centers are also located within Houston, including Debakey Heart and Vascular Institute and Texas Children’s Hospital.
“Our presence in Houston will be instrumental to the success of our research operations at BIOLIFE4D” said Birla, Chief Science Officer, BIOLIFE4D. “Furthermore, access to collaboration with innovative biotechnology companies in the Houston area, in the heart of the Texas Medical Center, provides access to thought leaders in the field of heart research, thereby accelerating our research towards bioprinting human hearts.”
JLABS @ TMC is a 34,000-square-foot life science innovation center, located in Houston, Texas. The labs provide a flexible environment for start-up companies pursuing new technologies and research platforms to advance medical care. Through a "no strings attached" model, Johnson & Johnson Innovation (JJI) does not take an equity stake in the companies occupying JLABS and the companies are free to develop products - either on their own, or by initiating a separate external partnership with JJI or any other company.
BIOLIFE4D will be able to collaborate with renowned area medical centers such as MD Anderson, Baylor College of Medicine, Methodist, UTHealth, and Rice University.
To see how BIOLIFE4D’s process starts with a patient’s own cells and ends with a functional human heart ready for transplant, please watch this video.
To learn more about BIOLIFE4D and to express interest in investing please watch this video or visit https://biolife4d.com/invest/.
About BIOLIFE4D
BIOLIFE4D is a pioneering biotech company laser focused on leveraging advances in life sciences and tissue engineering to 3D bioprint a viable human heart suitable for transplant – lifesaving technology that gives patients the gift of time. With BIOLIFE4D, a patient-specific, fully functioning heart will be created through 3D bioprinting using the patient’s own cells – eliminating the well-known challenges of organ rejection and long donor waiting lists that plague existing organ transplant methods. Financed through equity crowdfunding, BIOLIFE4D is driving a movement to transform the treatment of heart disease, the leading cause of death among both men and women globally. Learn more and invest at biolife4d.com. Connect with us on social media on Twitter (@BIOLIFE4D), Facebook, LinkedIn, and Instagram.
Securities are offered pursuant to a Regulation A+. Investors are encouraged to read the Offering Circular and exhibits and consult with their tax, legal, or financial professional prior to investing.
Forward Looking Statements
We caution you that, whether or not expressly stated, certain statements made in this news release that reflect management's expectations regarding future events and economic performance are forward-looking in nature and, accordingly, are subject to risks and uncertainties. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as "believe," "expect," "anticipate," "plan," "potential," "continue" or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements.
Media Contact
Matthew Bretzius
FischTank Marketing and PR
biolife4d@fischtankpr.com